Security
Scholar Rock Holding Corporation Common Stock · SRRK
SRRKNASDAQCommon stockCurrentCIK 1727196Updated Nov 17, 2026
SRRK price & chart
Loading TradingView…
NASDAQ:SRRK on TradingView ↗About the company
Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Following FDA approval in September 2026, Scholar Rock is commercializing ISEMBLYD (apitegromab-mstn) in the U.S. for people living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. The Company plans to expand access to ISEMBYLD globally, in up to 50 countries worldwide, subject to regulatory approvals.
In the news
Seeking Alpha
Scholar Rock Holding Corporation (SRRK) Presents at UBS Global Biopharma Conference 2026 Transcript ↗
Scholar Rock anticipates CHMP opinion in H1 2027 as it monetizes a $205M priority review voucher ↗
Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript ↗
SEC disclosures
Scholar Rock Holding Corp files 8-K: Material Event ↗
Recent filings
SCHEDULE 13G/A - filed by WELLINGTON MANAGEMENT GROUP LLP regarding Scholar Rock Holding Corp
SCHEDULE 13G/A - filed by PRICE T ROWE ASSOCIATES INC /MD/ regarding Scholar Rock Holding Corp
10-Q filing
Entry into a Material Definitive Agreement · Results of Operations and Financial Condition · Regulation FD Disclosure
Items 1.01, 2.02, 7.01
4 filing
Show 5 more recent filings
4 filing
Regulation FD Disclosure
Items 7.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13G/A - filed by Redmile Group, LLC regarding Scholar Rock Holding Corp
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 411,718,000Source | 179,133,000Source | 523,543,000Source | 340,045,000Source | 226,865,000Source | 535,254,000Source | 407,553,000Source | 267,285,000Source | 404,272,000Source | 474,922,000Source | 311,035,000Source | 358,168,000Source |
| Property, Plant and Equipment, NetUSD | 2,116,000Source | 3,156,000Source | 1,166,000Source | 2,437,000Source | 3,549,000Source | 1,435,000Source | 2,639,000Source | 4,038,000Source | 1,705,000Source | 2,761,000Source | 4,600,000Source | 7,384,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 286,770,000Source | 76,391,000Source | 437,091,000Source | 152,925,000Source | 93,372,000Source | 430,543,000Source | 137,926,000Source | 91,979,000Source | 323,527,000Source | 177,878,000Source | 101,855,000Source | 103,275,000Source |
| Assets, CurrentUSD | 390,711,000Source | 152,927,000Source | 507,183,000Source | 319,126,000Source | 199,137,000Source | 515,284,000Source | 385,247,000Source | 246,933,000Source | 385,147,000Source | 451,165,000Source | 288,194,000Source | 328,024,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 21,081,000Source | 13,862,000Source | 15,095,000Source | 24,113,000Source | 8,643,000Source | 35,340,000Source | 20,872,000Source | 8,501,000Source | 17,584,000Source | 13,887,000Source | 8,256,000Source | 12,663,000Source |
| Operating Lease, Right-of-Use AssetUSD | 11,767,000Source | 16,834,000Source | 8,620,000Source | 13,111,000Source | 17,975,000Source | 10,139,000Source | 14,403,000Source | 9,805,000Source | 10,382,000Source | 15,644,000Source | 11,417,000Source | 18,543,000Source |
| Other Assets, NoncurrentUSD | 3,317,000Source | 3,809,000Source | 2,767,000Source | 2,964,000Source | 3,797,000Source | 4,589,000Source | 2,857,000Source | 4,102,000Source | 3,231,000Source | 2,945,000Source | 4,417,000Source | 1,719,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 166,723,000Source | 99,937,000Source | 269,759,000Source | 106,752,000Source | 93,245,000Source | 259,241,000Source | 95,220,000Source | 84,512,000Source | 158,784,000Source | 106,288,000Source | 85,817,000Source | 97,933,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 99,000Source | 80,000Source | 122,000Source | 96,000Source | 80,000Source | 119,000Source | 95,000Source | 80,000Source | 108,000Source | 94,000Source | 76,000Source | 52,000Source |
| Additional Paid in CapitalUSD | 1,454,468,000Source | 935,249,000Source | 1,768,581,000Source | 1,340,608,000Source | 925,376,000Source | 1,681,368,000Source | 1,309,547,000Source | 916,017,000Source | 1,545,940,000Source | 1,291,095,000Source | 901,471,000Source | 771,699,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,209,689,000Source | -856,261,000Source | -1,516,060,000Source | -1,107,469,000Source | -791,782,000Source | -1,406,164,000Source | -997,438,000Source | -733,274,000Source | -1,300,654,000Source | -922,715,000Source | -676,421,000Source | -510,632,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 117,000Source | 128,000Source | 1,141,000Source | 58,000Source | -54,000Source | 690,000Source | 129,000Source | -50,000Source | 94,000Source | 160,000Source | 92,000Source | -884,000Source |
| Stockholders' Equity Attributable to ParentUSD | 244,995,000Source | 79,196,000Source | 253,784,000Source | 233,293,000Source | 133,620,000Source | 276,013,000Source | 312,333,000Source | 182,773,000Source | 245,488,000Source | 368,634,000Source | 225,218,000Source | 260,235,000Source |
| Liabilities and EquityUSD | 411,718,000Source | 179,133,000Source | 523,543,000Source | 340,045,000Source | 226,865,000Source | 535,254,000Source | 407,553,000Source | 267,285,000Source | 404,272,000Source | 474,922,000Source | 311,035,000Source | 358,168,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 61,972,000Source | 39,372,000Source | 72,242,000Source | 50,435,000Source | 32,987,000Source | 59,643,000Source | 37,574,000Source | 37,506,000Source | 55,419,000Source | 46,936,000Source | 32,741,000Source | 36,389,000Source |
| Operating Lease, Liability, CurrentUSD | 5,325,000Source | 6,041,000Source | 6,316,000Source | 5,212,000Source | 6,198,000Source | 6,076,000Source | 5,497,000Source | 7,619,000Source | 5,550,000Source | 5,774,000Source | 7,408,000Source | 7,852,000Source |
| Accounts Payable, CurrentUSD | 6,765,000Source | 4,071,000Source | 10,995,000Source | 1,104,000Source | 3,315,000Source | 9,218,000Source | 4,437,000Source | 2,868,000Source | 10,303,000Source | 10,095,000Source | 3,465,000Source | 3,994,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,140,000Source | 10,466,000Source | 1,314,000Source | 6,561,000Source | 11,773,000Source | 2,984,000Source | 7,905,000Source | 2,412,000Source | 3,656,000Source | 9,206,000Source | 4,392,000Source | 11,800,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 49,882,000Source | 29,260,000Source | 54,931,000Source | 44,119,000Source | 21,886,000Source | 44,349,000Source | 27,640,000Source | 21,411,000Source | 39,566,000Source | 31,067,000Source | 20,449,000Source | 24,321,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 99,611,000Source | 50,099,000Source | 196,203,000Source | 49,756,000Source | 48,485,000Source | 196,614,000Source | 49,741,000Source | 44,594,000Source | 99,709,000Source | 50,146,000Source | 48,684,000Source | 49,744,000Source |
| Preferred Stock, Value, Issued | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -105,510,000Source | -74,723,000Source | -377,939,000Source | -246,294,000Source | -165,789,000Source | -134,502,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 18,245,000Source | 13,413,000Source | 75,600,000Source | 36,628,000Source | 27,142,000Source | 27,701,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,085,000Source | -5,658,000Source | 208,000Source | 6,630,000Source | -529,000Source | -251,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -82,101,000Source | -78,675,000Source | -300,035,000Source | -200,949,000Source | -145,226,000Source | -132,694,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -5,335,000Source | 34,554,000Source | 218,687,000Source | -76,056,000Source | 41,141,000Source | -171,698,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 68,000Source | 271,000Source | 602,000Source | 98,000Source | 71,000Source | 1,064,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 193,786,000Source | 4,169,000Source | 228,399,000Source | 353,028,000Source | 102,574,000Source | 194,832,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | 2,000Source | — | — | 3,000Source | — |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 103,058,000Source | 25,520,000Source | 25,520,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | -39,952,000Source | — | 76,023,000Source | -1,511,000Source | -109,560,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 290,577,000Source | 78,798,000Source | 440,898,000Source | 155,332,000Source | 434,350,000Source | 140,333,000Source | 327,334,000Source | 180,285,000Source | 104,262,000Source | 105,773,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,368,000Source | 1,500,000Source | 6,066,000Source | 6,617,000Source | 6,399,000Source | 4,372,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 46,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 666,000Source | — | -2,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 18,331,000Source | 9,650,000Source | 19,662,000Source | 24,433,000Source | 18,245,000Source | 13,413,000Source | 75,600,000Source | 36,628,000Source | 27,142,000Source | 27,701,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 34,000Source | 448,000Source | 423,000Source | 253,000Source | 274,000Source | 720,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | -3,000Source | — | — | — | -11,000Source | -33,000Source |
| General and Administrative ExpenseUSD | — | — | 53,064,000Source | 16,061,000Source | 50,667,000Source | 49,708,000Source | 50,202,000Source | 28,412,000Source | 176,205,000Source | 67,504,000Source | 49,395,000Source | 43,119,000Source |
| InterestExpenseNonoperatingUSD | — | — | 1,334,000Source | 1,744,000Source | 4,518,000Source | 1,206,000Source | 2,302,000Source | 1,818,000Source | 6,893,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -102,220,000Source | -64,479,000Source | -109,896,000Source | -110,031,000Source | -105,510,000Source | -74,723,000Source | -377,939,000Source | -246,294,000Source | -165,789,000Source | -134,502,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,330,000Source | 301,000Source | -995,000Source | 2,078,000Source | -3,494,000Source | 2,367,000Source | 6,706,000Source | 5,760,000Source | 5,506,000Source | -132,000Source |
| Operating ExpensesUSD | — | — | 103,550,000Source | 64,780,000Source | 108,901,000Source | 112,109,000Source | 102,016,000Source | 77,090,000Source | 384,645,000Source | 252,054,000Source | 171,295,000Source | 167,563,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | 7,000,000Source | 8,300,000Source | 8,700,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -69,000Source | -38,000Source | -570,000Source | -127,000Source | -790,000Source | -44,000Source | -301,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 98,000,000Source | — | 91,660,000Source | 324,414,000Source | 97,709,000Source | 195,315,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | 24,667,000Source | 24,668,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 3,473,000Source | 5,020,000Source | 23,811,000Source | 19,114,000Source | 1,399,000Source | 492,000Source |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | —Source | —Source | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | 0Source | — | 0Source | — | — | 33,193,000Source |
| Operating Income (Loss)USD | — | — | -103,550,000Source | -64,780,000Source | -108,901,000Source | -112,109,000Source | -102,016,000Source | -77,090,000Source | -384,645,000Source | -252,054,000Source | -171,295,000Source | -134,370,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -69,000Source | -38,000Source | -570,000Source | -127,000Source | -790,000Source | -44,000Source | -301,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -102,220,000Source | -64,479,000Source | -109,896,000Source | -110,031,000Source | -105,510,000Source | -74,723,000Source | -377,939,000Source | -246,294,000Source | -165,789,000Source | -134,502,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.9Source | -0.66Source | -0.84Source | -0.98Source | -0.83Source | -0.67Source | -3.29Source | -2.47Source | -1.99Source | -2.26Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.9Source | -0.66Source | -0.84Source | -0.98Source | -0.83Source | -0.67Source | -3.29Source | -2.47Source | -1.99Source | -2.26Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 113,729,850Source | 97,050,637Source | 130,612,734Source | 112,703,014Source | 127,277,144Source | 111,838,272Source | 114,701,154Source | 99,838,102Source | 83,347,086Source | 59,611,656Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 113,729,850Source | 97,050,637Source | 130,612,734Source | 112,703,014Source | 127,277,144Source | 111,838,272Source | 114,701,154Source | 99,838,102Source | 83,347,086Source | 59,611,656Source |
| Interest Expense (non-operating)USD | — | — | 1,334,000Source | 1,744,000Source | 4,518,000Source | 1,206,000Source | 2,302,000Source | 1,818,000Source | 6,893,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 335,000Source | 393,000Source | 1,658,000Source | 1,937,000Source | 2,844,000Source | 2,986,000Source |
| General and Administrative ExpenseUSD | — | — | 53,064,000Source | 16,061,000Source | 50,667,000Source | 49,708,000Source | 50,202,000Source | 28,412,000Source | 176,205,000Source | 67,504,000Source | 49,395,000Source | 43,119,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -377,734,000Source | — | — | — |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | 6,300,000Source | 6,600,000Source | 6,500,000Source | 4,700,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,330,000Source | 301,000Source | -995,000Source | 2,078,000Source | -3,494,000Source | 2,367,000Source | 6,706,000Source | 5,760,000Source | 5,506,000Source | -132,000Source |
| Operating ExpensesUSD | — | — | 103,550,000Source | 64,780,000Source | 108,901,000Source | 112,109,000Source | 102,016,000Source | 77,090,000Source | 384,645,000Source | 252,054,000Source | 171,295,000Source | 167,563,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | 7,000,000Source | 8,300,000Source | 8,700,000Source |
| Research and Development ExpenseUSD | — | — | 50,486,000Source | 48,719,000Source | 58,234,000Source | 62,401,000Source | 51,814,000Source | 48,678,000Source | 208,440,000Source | 184,550,000Source | 121,900,000Source | 124,444,000Source |
Filing attachments
srrk-ex99_1.htm · 8-K · 2026-11-10
Exhibit 99.1 Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights • U.S. launch of ISEMBYLD™ (apitegromab-mstn), the first and only muscle-targeted therapy for children and adults living with spinal muscular atrophy (SMA), underway following September 11, 2026 FDA approval • ISEMBYLD shipped to specialty network prior to quarter-end, reflecting Q3 2026 ISEMBYLD revenue of $0.6 million • Strong early patient and physician demand for ISEMBYLD, with initial p…
Read attachment ↗srrk-ex99_2.htm · 8-K · 2026-11-10
Q3 2026 Earnings Call November 10, 2026 © 2026 Scholar Rock, Inc. All rights reserved. SMA, Spinal Muscular Atrophy. © 2026 Scholar Rock, Inc. All rights reserved. Q3 2026 Earnings Call 01 02 03 04 05 BUSINESS OVERVIEW David L. Hallal Chairman & Chief Executive Officer COMMERCIAL UPDATE Keith Woods Chief Operating Officer R&D PROGRESS Akshay Vaishnaw, M.D., Ph. D. President of R&D FINANCIAL RESULTS Vikas Sinha Chief Financial Officer Q&A SESSION Forward-Looking Statements © 2026 Scholar Rock, …
Read attachment ↗tm2625362d1_ex99-1.htm · 8-K · 2026-09-14
EX-99.1 2 tm2625362d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) September 11, 2026 ISEMBYLD is approved for use in all adults and children ≥2 years of age with SMA who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment ISEMBYLD recommended dose of 10 mg/kg showed a robust, clinically me…
Read attachment ↗tm2625362d1_ex99-2.htm · 8-K · 2026-09-14
EX-99.2 3 tm2625362d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 ISEMBYLD (apitegromab-mstn) FDA Approval Conference Call September 14, 2026 © 2026 Scholar Rock, Inc. All rights reserved. ────────────────────────────────────────────────── 2 Forward-Looking Statements Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock Holding Corporation and Scholar Rock, Inc. (collectively, “Scholar Rock”), including without limita…
Read attachment ↗srrk-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 srrk-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date • FDA review of second fill-finish facility progressing; Data pack…
Read attachment ↗srrk-20260507xex99d1.htm · 8-K · 2026-05-07
EX-99.1 2 srrk-20260507xex99d1.htm EX-99.1 Exhibit 99.1 Exhibit 99.1 Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights • FDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action date • Accepted apitegromab BLA includes two fill-finish facilities, Catalent Indiana LLC (part of Novo Nordisk), and …
Read attachment ↗